partnering

News

Novo Nordisk joins molecular glue club with Neomorph deal

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph t

News

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be ac

News

Roche, PathAI team up on AI companion diagnostics

Roche has turned to artificial intelligence specialist PathAI to accelerate development of digital pathology technologies that can be used to match patients with drug treatments and s

News

Takeda grabs late-stage haematology drug from Protagonist

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics.

News

Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt

Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma pa

News

AbbVie is big pharma’s first mover in ‘in situ’ cell therapy

AbbVie has signed a wide-ranging collaboration with Umoja Biopharma in the area of ‘in situ’ or in vivo cell therapy, an emerging strategy that does away with the need to

Novo Nordisk joins molecular glue club with Neomorph deal

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

Roche, PathAI team up on AI companion diagnostics

Takeda grabs late-stage haematology drug from Protagonist

Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt

AbbVie is big pharma’s first mover in ‘in situ’ cell therapy

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

partnering

Editor's Picks